ReportGem ReportGem 中文

TODAY'S MARKET INTELLIGENCE

BofA Upgrades Moderna to Neutral with $170 PT After 177% Rally on Cancer Vaccine

Published: 2026-08-20 15:32:38Category: financeHeat: 72

English summary

Bank of America upgraded Moderna to Neutral with a $170 price objective after the stock surged 177% following positive data for its personalized cancer vaccine intismeran in adjuvant melanoma.

The English text is machine translated and may require verification against the Chinese version.

Browse today's intelligence

Related research and intelligence

Inflation Target Challenged, What's Next for ECB?2026-09-01US-Iran escalation on Larak Island keeps oil prices range-bound2026-09-01Escalating Mine Warfare and Island Standoff: Oil Remains Rangebound Amid US-Iran Balance2026-09-01RBNZ September hike to 2.75% nearly certain, October path data-dependent2026-09-01US Treasury Secretary Urges BOJ to Hike Rates; 10-Year JGB Yield Hits 30-Year High2026-09-01Higher U.S. Treasury Yields and Oil Prices Support Dollar; Dollar Index Approaches 99.50, Nonfarm Payrolls Key Catalyst2026-09-01